LakeShore Biopharma Co., Ltd LSBCF
0.07 USD 0.00 (+0.00%)
At closeSep 4, 2026, 4:00 PM EDT
0.067 Day range 0.067
0.0278 52-week range 1.48
- YTD
- -92.02%
- 1 year
- -93.02%
News
globenewswire.com LSBCF Investors Have Opportunity to Join LakeShore Biopharma Co., Ltd Fraud Investigation with the Schall Law Firm LOS ANGELES, May 08, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of LakeShore…
businesswire.com LSB Industries, Inc. Schedules 2025 Third Quarter Results Release for Wednesday, October 29th and Conference Call for Thursday, October 30th OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (“LSB”) (NYSE: LXU), today announced that it will release its financial results for the third quarter ended September 30, 2025 on Wednesday,…
prnewswire.com LakeShore Biopharma Announces Transition to OTC Market Following Nasdaq Delisting BEIJING , Sept. 22, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,…
prnewswire.com LakeShore Biopharma Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee BEIJING , Sept. 10, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB, "LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,…
prnewswire.com LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee BEIJING , Aug. 28, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,…
businesswire.com LSB Industries, Inc. to Participate in Upcoming Investor Conferences OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (“LSB”), (NYSE: LXU), today announced that its Chairman & Chief Executive Officer, Mark Behrman will be participating in the following…
prnewswire.com LakeShore Biopharma Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company BEIJING , Aug. 18, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,…
prnewswire.com LakeShore Biopharma Announces Fiscal Year 2025 Financial Results Total revenue reached RMB615.0 million, representing 7.2% year-over-year growth Gross profit rose to RMB507.2 million, up 11.3% year-over-year Gross margin improved to 82.5% from 79.5% in Fiscal Year…
businesswire.com LSB Industries, Inc. Reports Operating Results for the 2025 Second Quarter OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (NYSE: LXU) (“LSB,” “we,” “us,” “our,” or the “Company”) today announced results for the second quarter ended June 30, 2025. Second Quarter 2025…
businesswire.com LSB Industries, Inc. Schedules 2025 Second Quarter Results Release for Tuesday, July 29th and Conference Call for Wednesday, July 30th OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (“LSB”) (NYSE: LXU), today announced that it will release its financial results for the first quarter ended June 30, 2025 on Tuesday, July 29,…
prnewswire.com LakeShore Biopharma Announces US$15 Million Private Placement Financing BEIJING , July 8, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) (the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and…
businesswire.com LSB Industries, Inc. to Participate in UBS Energy Transition and Decarbonization Conference on Wednesday, May 14th OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (NYSE: LXU) (“LSB” or the “Company”), today announced that its Vice President of Clean Energy, Jakob Krummenacher, will participate in the UBS…
businesswire.com LSB Industries, Inc. Reports Operating Results for the 2025 First Quarter OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (NYSE: LXU) (“LSB,” “we,” “us,” “our,” or the “Company”) today announced results for the first quarter ended March 31, 2025. First Quarter 2025…
prnewswire.com LakeShore Biopharma Announces the Official Launch of a Novel Packaging Solution for YSJA™ Rabies Vaccine (Vero Cell) Revolutionizing Vaccination Safety with Needle-Free Reconstitution Technology BEIJING , April 23, 2025 /PRNewswire/ -- On April 18, 2025, LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) ("LakeShore…
businesswire.com LSB Industries, Inc. Schedules 2025 First Quarter Results Release for Tuesday, April 29th and Conference Call for Wednesday, April 30th OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (“LSB”) (NYSE: LXU), today announced that it will release its financial results for the first quarter ended March 31, 2025 on Tuesday, April 29,…
businesswire.com LSB Industries, Inc. Appoints Riccardo Bertocco as an Independent Member of the Board of Directors OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (NYSE: LXU) (“LSB” or the “Company”), today announced that it has appointed Riccardo Bertocco as an independent member of the Board of Directors…
businesswire.com LSB Industries, Inc. Reports Operating Results for the 2024 Fourth Quarter and Full Year and Provides Product Sales Volume Outlook for 2025 OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (NYSE: LXU) (“LSB,” “we,” “us,” “our,” or the “Company”) today announced results for the fourth quarter and full year ended December 31, 2024.…
businesswire.com LSB Industries, Inc. Schedules 2024 Fourth Quarter and Full Year Financial Results Release for Wednesday, February 26th and Conference Call for Thursday, February 27th OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (“LSB”) (NYSE: LXU), today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2024 on…
prnewswire.com LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance Achieved total revenue of RMB 371.9 million, reflecting a growth of 36.2% YoY Achieved gross profit of RMB 307.3 million, a growth of 39.1% YoY Gross margin increased to 82.6% from 80.9% in the same…
globenewswire.com LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China BEIJING, Dec. 12, 2024 (GLOBE NEWSWIRE) -- LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) (“LakeShore Biopharma” or the “Company”), a leading global biopharmaceutical company focused on the innovation…